Merck Anti-Emetic Emend Adds Postoperative Nausea Indication
This article was originally published in The Pink Sheet Daily
Emend represents the first new class of therapy for the management of PONV in more than 10 years, Merck says.
You may also be interested in...
Firm will respond “within the next few months” to May 3 letter, Merck tells “The Pink Sheet” DAILY.
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13